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ABSTRACT
In an in vitro screening for human carbonic anhydrase (hCA) inhibiting agents from higher plants, the pet-
roleum ether and ethyl acetate extracts of Magydaris pastinacea seeds selectively inhibited hCA IX and
hCA XII isoforms. The phytochemical investigation of the extracts led to the isolation of ten linear furocou-
marins (1–10), four simple coumarins (12–15) and a new angular dihydrofurocoumarin (11). The structures
of the isolated compounds were elucidated based on 1D and 2D NMR, MS, and ECD data analysis. All iso-
lated compounds were inactive towards the ubiquitous cytosolic isoform hCA I and II (Ki> 10,000nM)
while they were significantly active against the tumour-associated isoforms hCA IX and XII. Umbelliprenin
was the most potent coumarin inhibiting hCA XII isoform with a Ki of 5.7 nM. The cytotoxicity of the most
interesting compounds on HeLa cancer cells was also investigated.
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1. Introduction
Coumarins occur as secondary metabolites in many plant species,
but above all, in Apiaceae, Rutaceae, Asteraceae and Fabaceae.
Natural coumarins have attracted considerable attention because
of their wide range of biological activities including anti-HIV1,
antimicrobial2, anticancer3,4, anticoagulant5, antioxidant6, and
antiinflammatory7 properties. The discovery of the natural couma-
rin 6-(1S-hydroxy-3-methylbutyl)-7-methoxy-2H-chromen-2-one as
inhibitor of carbonic anhydrase (CA, EC 4.2.1.1) extended the spec-
trum of the pharmacological activity of coumarins also towards
this class of enzymes8.
CAs are ubiquitous metallo-enzymes, which are widely present
in prokaryotes and eukaryotes. Sixteen different human (h) CA iso-
forms (I–XV, VA and VB) are present in mammals. These enzymes
catalyse a very simple but essential physiological reaction of the
life cycle of many organisms, the reversible hydration of carbon
dioxide to bicarbonate and protons. As a consequence, CAs par-
ticipate in various physiological and pathological processes and
the deregulation of CA activity is associated with disorders and
diseases such as cancer9, glaucoma10, epilepsy11 and obesity12.
Not surprisingly, hCA inhibitors have been intensively studied and
several are in clinical use for diverse pathologies10,13,14. However,
the systemic administration of hCA inhibitors (hCAIs) causes a
wide range of side effects due to the lack of isozyme selectivity
that leads to inhibition of the ubiquitous hCA I and II isoforms.
Accordingly, there is a continuous search of isoform-selective CAIs
which should not inhibit the off-target CAI and II. The transmem-
brane hCA IX and XII are well-known tumour-associated isoforms
and are overexpressed in many hypoxic tumours showing a
restricted expression in normal tissues. In particular, under hypoxic
conditions CA IX and XII decrease extracellular pH and promote
tumour cell survival and invasion in hypoxic microenviron-
ments15,16. For this reason, hCA IX and XII are attractive anticancer
drug targets. Few natural coumarins have been evaluated as
inhibitors of hCA IX and XII isoforms8,17,18 but some of them were
found active in the nanomolar range18.
Continuing our search for biologically active secondary metab-
olites from Sardinian higher plants19,20, we have found that the
petroleum ether and ethyl acetate extracts of Magydaris pastina-
cea seeds exhibited potent inhibitory activity against hCA IX and
XII. As a consequence, in order to identify the active compounds,
a phytochemical investigation of the extracts was performed.
Magydaris pastinacea (Lam.) Paol. (Apiaceae) [syn.: Magydaris
tomentosa] is a plant that spontaneously grows in few regions of
Mediterranean area such as Sicily, Sardinia, Corse, Baleares and
North Africa. Previous studies on the rhizomes of M. pastinacea
revealed as main metabolites coumarin and furocoumarin gluco-
sides with inhibitory activity on platelet aggregation21.
Furthermore, coumarins isolated from the flowers of the same
plant showed antibacterial and anticoagulant activities22 while a
more recent work on the petroleum ether extract of flowers
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reported the cytotoxicity of furocoumarins and simple
coumarins23.
2. Materials and methods
2.1. General experimental procedures
Optical rotations were measured in CHCl3 or MeOH at 25 C using
a Perkin-Elmer 241 polarimeter. Circular dichroism spectra were
recorded on a JASCO J-810 spectropolarimeter equipped with a
Peltier temperature controller using a 10mm path-length cell. All
measurements were performed in methanol at compound concen-
tration of 300 mM. Each reported spectrum represents the average
of 3 scans recorded with 1-nm step resolution. Observed ECD sig-
nals were converted to molar ellipticity [H] ¼ deg cm2 
dmol1. UV spectra were recorded on a GBC Cintra 5 spectropho-
tometer. NMR spectra of all isolated compounds were recorded at
25 C on Unity Inova 500NB high-resolution spectrometer (Agilent
Technologies, CA, USA) operating at 500MHz for 1H and 100MHz
for 13C, respectively. Spectra were measured in CDCl3 and CD3OD
and referenced against residual non-deuterated solvents. HRESIMS
were measured on an Agilent 6520 Time of Flight (TOF) MS instru-
ment. Column chromatography was carried out under TLC moni-
toring using silica gel (40–63lm, Merck), and Sephadex LH-20
(25–100 lm, Pharmacia). For vacuum-liquid chromatography (VLC),
silica gel (40–63 lm) (Merck) was used. TLC was performed on sil-
ica gel 60 F254 or RP-18 F254 (Merck). LiChrolut RP-18 (40–63lm)
500mg, 3mL (Merck) solid phase extraction (SPE) cartridges were
also used. Semi-preparative HPLC was conducted by means of a
Varian 920 LH instrument fitted with an autosampler module with
a 1000mL loop. The peak purities were monitored using a dual-
wavelength UV detector settled at 254 and 360 nm. The columns
were a 250 10mm Spherisorb silica, particle size 5 lm (Waters)
and a 300 7.5mm Polymeric Reversed Phase (PLRP-S 100 Å), par-
ticle size 8 lm (Varian).
2.2. Plant material
The seeds of M. pastinacea were collected in July 2017 at Siniscola
(Nuoro), Sardinia, Italy. The plant material was identified by Prof.
Marco Leonti (University of Cagliari, Department of Biomedical
Sciences). A voucher specimen (No. 0485) was deposited in the
Herbarium of the Department of Life and Environmental Science,
Drug Sciences Section, University of Cagliari.
2.3. Extraction and isolation
Air-dried and powdered seeds of M. pastinacea (720 g) were
ground and extracted with petroleum ether (3.5 L) by percolation
at room temperature to give 77.6 g dried extract. The remaining
plant material was then extracted with EtOAc (3 L), giving 42 g
dried extract.
An aliquot (20 g) of the petroleum ether extract was subjected
to Vacuum Liquid Chromatography (VLC) (silica gel, 90 g,
40–63lm) using a step gradient of n-hexane/ethyl acetate
(9:1–0:10, 500mL each) to yield 24 fractions. Based on the TLC
similarities, identical fractions were combined to give a total of
eight fractions (F1–F8). Fraction F3 (0.98 g) was separated by col-
umn chromatography (CC) over silica gel using toluene/CH2Cl2
(7:3) as eluent to isolate compound 15 (96mg). Fraction F4
(1.55 g) was chromatographed by CC over silica gel using hexane-
EtOAc (1:9) as eluent giving compound 12 (330mg). Fraction F7
(1.04 g) was purified by CC over silica gel, using CH2Cl2-EtOAc
(9.5:0.5) as eluent to give eight subfractions (F7.1–F7.8). F7.2
(11mg) was subjected to chromatography by Sephadex LH
(MeOH) yielding compound 1 (3mg). Subfraction F7.3 (110mg)
was further subjected to CC over silica gel using CH2Cl2 as eluent
to give compound 2 (2.5mg) and a white solid (90mg). The
obtained solid was purified further by PLRP HPLC using aceto-
nitrile : H2O (6:4, flow 2.5mL/min) as eluent to give compound 2
(1.5mg, tR 11.2min) and compound 3 (1.2mg, tR 13min).
Subfractions F.7.6 and F7.8 were purified by Sephadex LH-20
(MeOH) yielding compounds 8 (38.9mg) and 13 (170mg), respect-
ively. Fraction F8 (800mg), after purification by CC over Sephadex
LH-20 (MeOH), furnished compound 13 (670mg).
An aliquot (16.6 g) of the EtOAc extract was subjected to
Vacuum Liquid Chromatography (VLC) (silica gel, 80 g, 40–63lm)
using a step gradient of n-hexane/ethyl acetate/MeOH (9:0 : 0–0:1:
9, 500mL each) to yield 38 fractions. Based on the TLC similarities,
identical fractions were combined to give a total of ten fractions
(F1–F10). An aliquot (0.5 g) of F3 (3.74 g) was chromatographed
over silica gel using CH2Cl2 as eluent, giving compound 6
(61.2mg) and compound 7 (4.7mg). An aliquot (50mg) of F4
(1.56 g) was purified and an impure compound (12mg) that was
purified by PLRP HPLC using acetonitrile : H2O (7:3, flow 2mL/
min) as eluent to give compound 2 (3.9mg, tR 8.5min) and com-
pound 1 (2.1mg, tR 14.2min). Fraction F6 (0.18 g) was subjected
to CC over silica gel using CH2Cl2 : EtOAc (7.5:2.5) as eluent, giving
eight subfractions (F6.1–F6.8). Fraction F6.3 (41mg) was further
chromatographed by PLRP HPLC, using acetonitrile : H2O (5:5,
flow of 2mL/min) as eluent, to give compounds 4 (1mg, tR
13.2min) and 5 (1.3mg, tR 15.2min). Fraction F6.5 (6.5mg) was
separated by PLRP HPLC, using acetonitrile : H2O (5:5, flow of
2mL/min) as eluent, to give compounds 10 (0.9mg, tR 8.5min)
and 11 (2.8mg, tR 7.5min). An aliquot (40mg) of F7 (70mg) was
chromatographed on CC over Sephadex LH-20 (MeOH) to furnish
an impure compound (16mg) that was further purified by PLRP
HPLC using acetonitrile : H2O (5:5, flow 2mL/min) as eluent, to
give compound 11 (1.3mg, tR 11.0min), compound 10 (1mg,
tR 13min), compound 4 (1.2mg, tR 14.5min) and compound
5 (3.6mg, tR 15.5min). Fraction F8 (165mg) was subjected to CC
over Sephadex LH (MeOH), yielding four subfraction (F8.1–F8.4).
Subfraction F8.2 (34.8mg) was purified by CC over Sephadex LH-
20, followed by PLRP HPLC using acetonitrile : H2O (4:6, flow
2.0mL/min) as eluent, to give compound 14 (3.8mg, tR 13.5min).
Subfraction F8.3 (42.2mg) was purified by PLRP HPLC using aceto-
nitrile : H2O (4:6, flow 2.0mL/min) as eluent, to give compound
9 (5.1mg, tR 9.5min). Subfraction F8.4 (30mg), was further sub-
jected to CC over Sephadex LH-20 (MeOH) to yield compound
9 (2.7mg).
Magydarin (11): white powder; [a]25D þ 96.3 (c 0.05, CH2Cl2);
UV (MeOH) kmax (log e) 348 (8.5) nm; ECD (300mM, MeOH) k (De)
348 (þ2950) nm; 1H (CDCl3, 500MHz) and 13C (CDCl3, 100MHz)
NMR, see Table 1; HRTOFESIMS m/z 277.1078 [MþH]þ (calcd for
C15H16O5, 277.1076).
2.4. Semi-Synthesis of (1)-heraclenol acetate (10)
To a solution of ()-heraclenol (9) (38.9mg, 0.13mmol) in pyridine
(2mL) acetic anhydride (0.012mL, 0.13mmol) was added dropwise
and left at room temperature for 48 h. The crude product was
dried and purified by CC (Sephadex LH-20), using MeOH as eluent
to provide 24.9mg of (þ)-heraclenol acetate (10)24.
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2.5. Molecular modelling
The ligands were built within the Maestro platform. The most sta-
ble conformation has been determined by molecular mechanics
conformational analysis performed with Macromodel software ver-
sion 9.225 using the Merck Molecular Force Fields (MMFFs)26 and
GB/SA water implicit solvation model27, Polak-Ribier Conjugate
Gradient (PRCG) method, 5000 iterations and a convergence criter-
ion of 0.05 kcal/(mol Å). All the other parameters were left
as default.
The coordinates for CA enzyme were taken from the RCSB
Protein Data Bank28 (PDB code 4ww8)29. The protein was prepared
by using the Maestro Protein Preparation Wizard. Original water
molecules were removed. Molecular docking studies were per-
formed using the QMPL workflow protocol. Grids were defined
around the refined structure by centreing them on the co-crystal-
lized ligand. The other settings were left as default.
In order to better take into account the induced fit phenom-
ena, the most energetically favoured generated complexes were
fully optimised with the OPLS2005 force field in GB/SA implicit
water30. The optimisation process was performed setting 10,000
steps interactions up to the derivative convergence criterion equal
to 0.05 kJ/(molÅ). The resulting complexes were considered for
the binding modes graphical analysis with Pymol and Maestro.
2.6. Biological activity
2.6.1. Carbonic anhydrase inhibition assay
An Applied Photophysics stopped-flow instrument has been used
for assaying the CA catalysed CO2 hydration activity
31. Phenol red
(at a concentration of 0.2mM) was used as indicator, working at
the absorbance maximum of 557 nm, with 20mM Hepes (pH 7.5)
as buffer and 20mM Na2SO4 (for maintaining constant the ionic
strength), following the initial rates of the CA-catalysed CO2 hydra-
tion reaction for a period of 10–100 s. The CO2 concentrations
ranged from 1.7 to 17mM for the determination of the kinetic
parameters and inhibition constants. For each inhibitor, at least six
traces of the initial 5–10% of the reaction have been used for
determining the initial velocity. The uncatalyzed rates were deter-
mined in the same manner and subtracted from the total
observed rates. Stock solutions of inhibitor (0.1mM) were pre-
pared in distilled–deionized water, and dilutions up to 0.01 nM
were done thereafter with the assay buffer. Inhibitor and enzyme
solutions were preincubated together for 6 h at room temperature
prior to assay in order to allow for the formation of the E–I
complex. The inhibition constants were obtained by nonlinear
least-squares methods using PRISM 3 and the Cheng–Prusoff
equation, as reported earlier32,33, and represent the mean from at
least three different determinations. All CA isoforms were recom-
binant ones obtained in-house as reported earlier34.
2.6.2. Cytotoxic assay
2.6.2.1. Cell culture. Human carcinoma HeLa cell line was obtained
from the American Type Culture Collection (ATCC, Rockville, MD).
Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM)
with high glucose, supplemented with 10% foetal calf serum
(FCS), penicillin (100 units/mL)–streptomycin (100 lg/mL), and
2mM L-glutamine in a 5% CO2 incubator at 37 C. Subcultures of
the HeLa cells were grown in T-75 culture flasks and passaged
with a trypsin-EDTA solution. Cell culture materials were pur-
chased from Invitrogen (Milan, Italy).
2.6.2.2. MTT assay. The in vitro cytotoxic effect of coumarins 5,
9–12, 15 was evaluated in cancer HeLa cells by the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reduction
assay35. Cancer cells were seeded in 96-well plates (density of
3 104 cells/mL) in 100lL of medium and cultured for 48 h (80%
of cell confluence). Cells were subsequently incubated for 48 h
with various concentrations (0.1–100 lM, dissolved in DMSO) of
coumarins in culture medium (treated cells). Treated cells were
compared for viability to untreated cells (control cells) and
vehicle-treated cells (incubated for 48 h with an equivalent volume
of DMSO; the maximal final concentration was 1%). After the cell
medium removing and washing, cells were subjected to the MTT
test35. After incubation (3 h), colour development was measured at
570 nm with an Infinite 200 auto microplate reader (Infinite 200,
Tecan, Austria); the absorbance is proportional to the number of
viable cells. Two independent experiments were performed. The
results were calculated as the percentage of cell viability in com-
parison with non-treated control cells and expressed as IC50 value
(the concentration of compound that reduces the cell viability
to 50%).
3. Results and discussion
3.1. Isolation and characterisation
The petroleum ether and ethyl acetate extracts of M. pastinacea
showed high potency to inhibit hCA IX and XII isoforms (Table 2)
and were therefore subjected to fractionation by silica gel vac-
uum-liquid chromatography (VLC), column chromatography (silica
gel and Sephadex LH 20) and semi-preparative HPLC (Polymeric
RP-HPLC) to give one new angular dihydrofurocoumarin (11)
along with ten linear furocoumarins (1–10) and four simple cou-
marins (12–15) (Figure 1).
The HR-ESIMS of compound 11 showed a molecular ion at m/z
277.1078 (MþH)þ which is in accordance with the molecular for-
mula C15H16O5 (calcd. 277.1076). The
1H NMR spectrum of com-
pound 11 showed two doublets at 6.23 (H-3, J¼ 9.5 Hz) and 7.59
(H-4, J¼ 9.5 Hz) ppm and a singlet at 6.77 ppm characteristic of a
coumarin nucleus substituted at C-6, C-7 and C-8 (Table 1). In the
high field spectrum region a further singlet at d 3.91 (3H, s) was
characteristic of a methoxy group, while two singlets at 1.25 (3H,
s) and 1.40 (3H, s) were assigned to two tertiary methyl groups.
Finally, the signals at 3.36 (2H, dd, J¼ 1.5, 9 Hz) and 4.86 (1H, t,
J¼ 9Hz) could be ascribed to a methylene and a methine group,
respectively. The 13C NMR spectrum highlighted 14 carbons of
Table 1. 1H NMR and 13C NMR Spectroscopic Data
for Compound 11 (CDCl3, d in ppm).
Compound 11
Position dC, type dH (J in Hz)
2 161.2, C
3 112.8, CH 6.23, d (9.5)
4 143.7, CH 7.59, d (9.5)
5 109.4, CH 6.77, s
6 141.8, C
7 146.1, C
8 115.5, C
9 152.5, C
10 112.8, C
20 92.2, CH 4.86, t, (9)
30 28.2 CH2 3.36, dd (1.5, 9)
40 71.8, C
50 24.1 CH3 1.25, s
60 26.1, CH3 1.40, s
OCH3 56.4, CH3 3.91, s
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which those at 161.2, 143.7 and 112.8 ppm were characteristic
respectively of C-2, C-3 and C-4 of a coumarin nucleus (Table 1).
The connectivity of each proton with its respective carbon has
been identified through HSQC experiment. In the HMBC spectrum,
the correlations between the aromatic proton at d 6.77 (1H, s) and
the carbons at 152.5, 146.1, 143. 7 and 141.8 ppm located this pro-
ton at position 5 of the coumarin system (Figure 2). This was con-
firmed by the fact that no cross-peak of this proton with the
carbon at 143.7ppm could be observed if it would be located at
C-6, C-7 or C-8. In the same spectrum the cross-peaks between the
signal at 1.25 (s) and the carbons at 26.1, 71.8 and 92.2ppm and
between the signal at 1.40 (s) ppm and the carbons at 24.1, 71.8
and 92.2 ppm, confirmed the presence of two geminal methyls.
Further correlations of the methylene protons at d 3.36 (2H,
dd, J¼ 1.5, 9 Hz) with the carbons at 71.8, 92.2, 115.5, 146.1 and
152.5 ppm fixed the 1,1-dimethyl-2-oxypropanol chain at C-8 of
the coumarin nucleus. In the HMBC experiment it could be
observed that the methoxyl group at 3.91 ppm was linked to the
coumarin nucleus on carbon at 141.8 ppm. This data, together
with the correlation between the aromatic proton at C-5 and car-
bon at 141.8 ppm, allowed us to place the methoxy group at C-6.
The absence of further aromatic protons and the presence of only
one alcohol group (d 1.58) in the proton spectrum, suggested the
cyclisation of the alcohol chain at position 7 of the coumarin ring.
HSQC, HMBC, and ROESY experiments allowed the complete
assignment of all signals and the identification of the structure as
reported in Figure 2.
The absolute configuration of the (þ)-diidrofurocoumarin 11
has been established studying its Electronic Circular Dicroism
(ECD) spectrum (Figure 3). The positive Cotton effect at 348 nm in
the ECD spectrum was ascribed to the n ! p electronic transi-
tion of the unsaturated lactone ring, which permitted the assign-
ment of the (2’S) absolute configuration based on the modified
octant rule36,37. In fact, the 1-hydroxy-1-methylethyl group was
located in the upper left (þ) octant. Compound 11 is a previously
undescribed diidrofurocoumarin and was named magydarin.
The absolute configuration of the (þ)-heraclenol acetate24 10
is not reported in the literature and therefore it has been estab-
lished through the acetylation of the isolated ()-heraclenol 9, for
which the S configuration has been previously assigned38,39. The
specific optical rotation of compound 9 ([a]D
25¼ 7.1) revealed
that its absolute configuration is S40. Acetylation with acetic
anhydride in pyridine of ()-S-heraclenol yielded S-heraclenol
acetate possessing a specific optical rotation [a]D
25 þ10. As conse-
quence, the natural (þ)-heraclenol acetate (10) must have an
absolute configuration S.
Compound 4 has been identified as trichoclin by comparison
with analytical and spectroscopic data reported in the literature41.
However, trichoclin contain a double bond whose geometric con-
figuration could not be determined by comparison with the data
reported in the literature. In order to assign the Z or E configur-
ation to the double bond, a ROESY spectrum of compound 4 was
recorded. The ROESY spectrum revealed a cross-peak between the
olefinic proton at d 5.74 (1H, t, J¼ 7Hz) and the oxymethylene
protons at 5.05 (2H, d, J¼ 7Hz) but the correlation between the
proton at d 5.74 with the methyl group at 1.87 (3H, s) ppm could
not be observed. This is well suited to an E geometry. In fact, a
3D molecular model of E-trichoclin highlighted that the distance
between the olefinic proton and the oxymethylene protons was
3.2 Å, whereas the distance between the same proton and the
methyl group was 4 Å. In the case of Z isomer, the distance of
3.9 Å between the olefinic proton and the oxymethylene protons
preclude any correlation whereas the short distance (2.3 Å) of the
methyl at d 1.87 with methine at 5.74 ppm should be enough to
give a cross-peak in the ROESY spectrum. Thus, compound 4 has
been identified as E-trichoclin.
Compound 5 has been identified as 5-methoxy-trichoclin by
comparison with analytical and spectroscopic data reported in the
literature41. With respect to trichoclin, compound 5 contained the
same chain and an additional methoxyl at position 5. As for E-tri-
choclin, the geometry of 5-methoxy-trichoclin double bond was
determined by ROESY experiments. In the ROESY spectrum the
cross peak between the olefinic proton at d 5.73 (1H, t, J¼ 7Hz)
and the methylene protons at d 4.89 (2H, d, J¼ 7.5 Hz), but not
the methyl group at d 1.87 (3H, s) could be observed. Therefore,
compound 5 has been identified as E-5-methoxy-trichoclin.
The structures of begapten (1), xanthotoxin (2), isopimpinellin
(3), imperatorin (6), phellopterin (7), heraclenin (8), (-)-heraclenol
(9), osthol (12), meranzin (13), 20-acetoxy-30-hydroxy-osthol (14)
and umbelliprenin (15) were deduced from the 1D and 2D NMR
spectra and confirmed by comparison of 1H- and 13C NMR data
with those reported in the literature22,41–47.
3.2. CA inhibition
The petroleum ether and ethyl acetate extracts together with all
the isolated coumarins were tested against four hCA isoenzymes
(I, II, IX and XII) (Table 2). The results showed that both extracts
were selective towards the tumour-associated CA IX and CA XII
since none was active against CA I and CA II up to the concentra-
tion of 100 ng/mL, whereas they were highly potent especially
against CA XII. The ethyl acetate extract was more potent com-
pared to the ether extract either against CA IX (Ki 1.74 ng/mL)
either against CA XII (Ki 0.5 ng/mL). The furocoumarins 1–9, 11
and coumarins 12, 15 inhibited both hCA IX and hCA XII in a
nanomolar range and they were completely inactive (Ki values >
10,000 nM) against hCA I and II, thus showing high selectivity over
these isoforms that are considered responsible for the side-effects
of CAIs. Interestingly, meranzin (13) and especially the furocou-
marin 10, inhibited exclusively the IX isoform of CA with Ki ratios
XII/IX > 5 and >52, respectively. On the contrary, compound 14
was a selective inhibitor of the XII isoform with a Ki ratio IX/XII
> 34.
Table 2. Inhibition data towards hCA I, II, IX, and XII of compounds 1–15.
Ki (nM)
Compound/extract hCA I hCA II hCA IX hCA XII
Petroleum ether >100a >100a 20a 0.8a
Ethyl acetate >100a >100a 1.74a 0.5a
1 >10,000 >10,000 1953 855.1
2 >10,000 >10,000 194.8 876.3
3 >10,000 >10,000 159.8 590.1
4 >10,000 >10,000 2339 550.0
5 >10,000 >10,000 1501 63.5
6 >10,000 >10,000 221.4 832.9
7 >10,000 >10,000 201.9 786.9
8 >10,000 >10,000 162.5 835.6
9 >10,000 >10,000 27.5 813.8
10 >10,000 >10,000 192.5 >10,000
11 >10,000 >10,000 150.9 623.0
12 >10,000 >10,000 2471 74.5
13 >10,000 >10,000 1888 >10,000
14 >10,000 >10,000 >10,000 290.9
15 >10,000 >10,000 266.4 5.8
AAZ 250.0 12.1 25.8 5.7
aData expressed in ng/mL.
Mean from three different assays, by a stopped flow technique (errors were in
the range of ±5–10% of the reported values).
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The most potent compound was umbelliprenin (15), with a Ki
value against CA XII of 5.8 nM, comparable to that of acetazola-
mide (AAZ) and demonstrated high selectivity over the off-target
CA I/II isoforms (Ki ratios I/XII > 1724). Also S-heraclenol (9) (Ki
27.5 nM), osthol (12) (KI 75 nM) and E-5-methoxy-trichoclin (5) (KI
63.5 nM) revealed a strong inhibitory effect towards CA IX (hera-
clenol) and CA XII (osthol and E-5-methoxy-trichoclin).
The SAR study pointed out that, in the 8-O-monosubstituted
furocoumarins (2, 4, 6, 8–10), the 2,3-dihydroxy-3-methylbutyl
moiety present in S-heraclenol (9), elicited the better inhibitory
profile towards hCA IX (Ki 27.5 nM). (þ)-S-heraclenol acetate (10)
compared to S-heraclenol, showed a reduction of inhibitory effects
towards hCA IX and hCA XII and most interestingly, a high select-
ivity towards the poorly expressed in healthy tissues hCA IX over
hCAXII with a selectivity index >52. Among furocoumarins 2, 4, 6,
8–10, we found that, in compounds 2, 4, 6, the introduction of a
methoxy group at C-5, giving compounds 3, 5, 7, furnished
enhanced inhibitory activity against hCA IX and hCA XII. In
Figure 1. Structures of the isolated coumarins.
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Figure 2. Main HMBC correlations of compound 11.
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particular, when the methoxy derivative 5 was compared with
E-tricholin (4), a 23-fold gain in potency towards the isoform CAXII
was observed.
As regards 7-methoxy-8-alkyl coumarins (12–14), osthol (12)
was the most potent of the hCAXII inhibitors (Ki 75 nM), highlight-
ing the importance of a prenyl chain at C-8.
The new angular dihydrofurocoumarin, magydarin (11), had
submicromolar inhibition of the validated cancer-associated iso-
zymes hCA IX and XII with Kis of 150.9 and 623 nM, respectively.
3.3. In silico modelling of the interaction of compounds 9, 11,
15 with CA XII
Compounds 9, 11 and 15 are characterised by an interesting
inhibitory activity towards the CA XII isoform, therefore, their
mechanism of action was investigated in more details by means
of computational methods. The protocol consisted of docking
experiments followed by the energy minimisation of the obtained
complexes. Recently, an interesting CA inhibition mechanism was
reported for coumarin derivatives8,48. This was also found as a
plausible mechanism of action of previously synthesised
compounds49.
Hence, the coumarin derivatives 15, 11 and 9 were docked to
understand if coumarin moiety could be hydrolysed by the Zn2þ
activated water molecule of the enzyme cavity, which acts as a
very potent nucleophile. These experiments showed that only
compound 15 was able to dock the coumarin portion close
enough to the Zn2þ (Figure 4(a)). Therefore, only this compound
could be hydrolysed. Instead, the compounds 11 and 9 binding
did not show the right orientation, probably due to the steric hin-
drance of the furocoumarin moiety (Figure 4(b,c)). Thus, both the
open conformations (E/Z) of compound 15 were subjected to
docking experiments in order to predict the binding mode of
hydrolysed forms. It is possible to see in Figure 5 as both diaster-
eoisomers are stabilised by several hydrogen bonds and p-p inter-
actions in the catalytic site. The hydrophobic portion fold up and
is stabilised by internal contacts and interactions with hydropho-
bic residues in the cavity. The predicted affinity of open com-
pounds was estimated to be better than the closed ones.
3.4. Cytotoxicity of compounds 5, 9–12 and 15 towards
cancer cells
On basis of the CA inhibition results, the growth inhibitory effect
of the most active/interesting coumarins (5, 9–12, 15) on HeLa
cancer cell line has been carried out (Table 3). Umbelliprenin (15)
showed moderate cytotoxicity against HeLa cells (IC50 75 lM)
and this result is in accord with other studies reporting the low
cytotoxicity of the compound towards the breast cancer cell
lines MCF and 4T150,51. However, umbelliprenin was effective to
inhibit tumour growth, angiogenesis and metastasis in mammary
tumour-bearing mice when intraperitoneally administrated52.
These data were confirmed by Zhang et al.53, which provided
evidence that umbelliprenin may inhibit the growth, invasion
and migration of gastric cancer cells by targeting the Wnt
signalling pathway, with little to no harm in the lung, heart
and kidney.
The low cytotoxicity of umbelliprenin may be related to its
very high liposolubility. This hypothesis was confirmed by the fact
that when umbelliprenin was encapsulated in nanoliposomes its
antiproliferative effect against 4T1 cells increased by five folds50.
Also osthol (12) showed only a moderate cytotoxicity with an IC50
of 98 lM but, as reported in previous works54,55, its cytotoxicity
greatly depends on the cancer cell line.
Most importantly, CA IX and CA XII are overexpressed in cancer
cells under hypoxic condition. Thus, the moderate antiproliferative
action showed by the isolated compounds is not surprising since
the assay has been carried out under normoxic conditions.
4. Conclusions
Fifteen coumarins were isolated from the seeds of M. pastinacea.
Magydarin (11) is new to the literature, while meranzine (13), xan-
thotoxin (2), E-trichoclin (4), E-5-methoxy-trichoclin (5), fellopterin
(7), (þ)-S-heraclenol acetate (10) and meranzine acetate hydrate
(14) were isolated for the first time from this plant. None of the
15 isolated coumarins have ever been evaluated for its inhibitory
activity on carbonic anhydrases. All isolated compounds were
inactive towards the ubiquitous cytosolic isoform hCA I and II (Ki
> 10,000 nM) that are considered responsible for the side-effects
of CAIs. On the contrary, they were significantly active against the
tumour-associated isoforms hCA IX and XII. CA XII was inhibited
with single-digit Ki by umbelliprenin (15) (5.7 nM) and with Kis
spanning in the nanomolar range (63.5–74.5 nM) by compounds 5
and 12. As regards the other tumour-associated isoform hCA IX, it
was potently inhibited by S-heraclenol (9) (Ki ¼ 27.5 nM) and, to a
lesser extent, by the new furocoumarin magydarin (11).
Particularly noteworthy is the selectivity of heraclenol acetate (10)
towards hCA IX over hCAI, hCAII and hCAXII (SI > 52). As far as
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Figure 3. ECD (left) and UV (right) spectra of compound 11.
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we know, umbelliprenin is the most potent natural coumarin
CA inhibitor.
Molecular docking experiments suggested that the most
potent coumarin 15 could be hydrolysed in the enzyme catalytic
pocket. Furthermore, docking experiments estimated that the
predicted affinity of open compounds was better than that of the
closed ones. Overall the computational methods helped to ration-
alise the strong activity of compound 15 towards the CA-XII iso-
form and to suggest a plausible mechanism of action that would
be further investigated to confirm it.
Figure 4. 3D representation of the putative binding mode obtained by docking experiments. (a,b) CA -XII-15 (c,d) CA -XII-11, (e,f) CA -XII-9 and the relative 2D repre-
sentation of the complexes stabilising interactions with the binding site residues represented with different colour depending on their chemical-physical properties:
green, hydrophobic; cyan, polar; violet, positive; red, negative charged residues; grey, metal atoms. Instead, magenta arrows indicate the formation of hydrogen bond
between protein and ligand, while grey lines indicate the interaction with the complexed ion.
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Future work on these compounds will attempt to synthesise ana-
logues with lower lipophilicity to achieve a better drug-like profile.
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